Dear Editor, In the midst of the COVID-19 pandemic, the Food and Drug Administration (FDA) approved the emergency use of hydroxychloroquine (HCQS), stating, "the known and potential benefits of chloroquine phosphate and hydroxychloroquine sulfate when used to treat COVID-19 outweigh the known and potential risks of such products". 1 On March 19, 2020, the President of the United States, Donald Trump, also stated that HCQS could be a "game-changer" for people with coronavirus without substantial evidence of the drug's efficacy, which led to increased purchasing of nonprescribed HCQS by the public and physicians for personal use, concerns regarding drug supply, and pharmacy shortages. [2] [3] While recent reports have described the potential consequences of a HCQS shortage on patients with systemic lupus erythematous (SLE), 2,4 a shortage of HCQS may also affect patients with dermatological conditions such as dermatomyositis, sarcoidosis, lichen planus, granuloma annulare, polymorphous light eruption and more, for which HCQS is prescribed under off-label indications (see Table 1 ) due to evidence of improvement after use of HCQS. [4] [5] [6] For example, Wolverton summarized the improvement of cutaneous sarcoidal granulomas in 17 patients after 4-12 weeks of treatment with HCQS 200-400mg daily, among other dermatoses. 5 On April 7, 2020, an article by the Consumer News and Business Channel reported a 21-year-old female with dermatomyositis, who has been using HCQS for the past eight years to reduce her flare-ups, which would otherwise result in muscle weakness, pain and her subsequent inability to complete instrumental activities of daily living including schoolwork. 3 The author states that the patient, "describes the possibility that she won't be able to access the drug as 'terrifying.' She only has a few more days before she runs out. Her pharmacy, which she contacted last week, is completely out of the medication." 3 Fortunately, to help combat a potential shortage, on April 7, 2020, the FDA approved an for several inflammatory airway diseases. 9 Overall, due to conflicting evidence we hope that further studies and clinical trials with larger sample size will meticulously assess the efficacy of HCQS in COVID-19, as well as its efficacy in combination with azithromycin or doxycycline.
With inconclusive findings on the efficacy of HCQS in COVID-19, we emphasize that it is critical for pharmaceutical companies, with cooperation from the public, to ensure that HCQS is not dispensed without prescription, so that this antimalarial is available to patients with dermatological and 